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DEPRESSION IN TYPE 1 DIABETIC YOUTH: INSULIN INJECTIONS VS.  
PUMPS 
ANDREW SHUMATE 
ABSTRACT 
Type 1 diabetes is an autoimmune disease that involves destruction of pancreatic 
cells that produce insulin. The disease typically presents in children and adolescents. The 
burden of disease management, fear of complications, and disruption of normal 
childhood that the disease causes place youth with type 1 diabetes at increased risk for 
developing depression compared to peers without the disease. The presence and severity 
of depression correlates with disease outcomes. Use of continuous subcutaneous insulin 
infusion pumps has been shown to improve youth’s quality of life compared to use of 
multiple daily insulin injections. Although quality of life measures are associated with the 
risk of developing depression, no studies have compared depression symptomatology in 
youth using insulin pumps to those using multiple daily insulin injections. The proposed 
project will assess relative depression symptomatology in youth ages 10-17 using insulin 
pumps and multiple daily insulin injections. The results of this proposed project could 
help inform clinicians’ decisions about whether to initiate type 1 diabetes therapy in 
youth with either insulin pumps or insulin injections. Given the financial burden of 
depression, it could also potentially encourage insurance companies to increase coverage 
of insulin pumps.  
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INTRODUCTION 
Background 
 
 Type 1 diabetes (T1D) is an autoimmune disease in which the immune system 
attacks and destroys the cells in the pancreas that produce insulin.1 Insulin is a hormone 
that allows the body’s cells to uptake glucose from the blood to use for energy.1 With 
T1D, there is inadequate production of insulin by the pancreas and, consequently, less 
glucose is taken up by cells.1 This results in hyperglycemia, or elevated blood glucose, 
which can lead to both acute and chronic complications.1 
 Both genetic and environmental factors, including viruses, diet, and the gut 
microbiome, have been implicated as potential causes of T1D.2 It is thought that 
environmental factors may trigger the disease in genetically predisposed individuals.2 
T1D typically presents in children and adolescents.3 The majority of youth with 
new-onset T1D present with polyuria, polydipsia, and weight loss and many present with 
diabetic ketoacidosis, a serious complication of the disease.3   
Given that T1D is characterized by insufficient insulin production and, 
consequently, elevated blood glucose levels, management of the disease involves 
frequent checks of blood glucose levels and administration of exogenous insulin, which 
increases cellular uptake of glucose in the blood, thereby keeping blood glucose levels 
within acceptable physiological boundaries.4 Methods for monitoring blood glucose 
levels include multiple daily fingersticks (also termed self-monitoring of blood glucose, 
or SMBG) and continuous glucose monitors (CGM).4 Methods for insulin administration 
include multiple daily injections (MDI) via syringes/needles or insulin pens, continuous 
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subcutaneous insulin infusion pumps (CSII), and closed-loop insulin pumps (also called 
the “artificial pancreas”).5  
 
Statement of the Problem 
 
 The prevalence of psychiatric disorders is quite high in youth with T1D6 and 
youth with T1D are at increased risk for developing psychiatric disorders compared to 
peers without T1D.7,41,42 In particular, depression has been found to be the most prevalent 
psychiatric disorder in youth with T1D.8 The significant burden of living with and 
managing a chronic, complex disease like T1D, the fear of acute and chronic 
complications, and the disruption in normal childhood activities and peer group 
interactions that T1D causes all contribute to the increased risk of depression in youth 
with T1D.9,43Additionally, the presence and severity of depression symptoms are 
associated with clinical outcomes in youth with T1D, as depression symptoms can 
impede a youth’s ability to motivate themselves to manage the disease and carry out tasks 
required to manage the disease.10,45,46,47 Depression in youth with T1D is also associated 
with increased hospitalizations for T1D complications.11  
 In recent years, use of CSII has become increasingly prevalent.12 Results from a 
limited number of studies suggest that CSII improves youths’ quality of life when 
compared to MDI.13,14,51,52 Although these quality of life measures are associated with the 
development of depression, there are no studies that specifically address the effect of 
CSII on the development of depression symptoms in youth compared to MDI.   
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Hypothesis 
 
 The burden of disease management, the fear of acute and chronic complications, 
and the disruption in normal childhood activities that T1D causes all place youth with 
T1D at increased risk for depression.9,43 The use of CSII has been shown to mitigate these 
factors.13,14,51,52 Therefore, the hypothesis is that youth who use CSII will develop 
decreased depression symptomatology compared to youth who use MDI.  
 
Objective and Specific Aims 
 
The proposed prospective cohort study will compare depression symptomatology in 
youth with T1D who use CSII versus those who use MDI. Specific aims of the proposed 
study include: 
• Assess relative depression symptomatology in youth with T1D using CSII versus 
MDI via the Children’s Depression Inventory (CDI) 
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REVIEW OF THE LITERATURE 
 
Pathophysiology of Type 1 Diabetes 
 
 The pancreas plays a key role in maintaining glucose homeostasis in the body.1 
Increased blood glucose levels (for example, following food intake) are sensed by beta 
cells in the pancreas.1 In turn, these beta cells secrete the hormone insulin into the blood. 
Insulin binds to receptors on cells throughout the body, which ultimately results in uptake 
of glucose by these cells and consequently a decrease in blood glucose levels.1  
 Type 1 diabetes (T1D) is an autoimmune disease.15 Normally, the immune system 
is regulated so that it only recognizes and attacks pathogens.15 However, autoimmune 
diseases occur when the immune system recognizes, attacks, and destroys healthy 
tissue.15 T1D involves an autoimmune attack on pancreatic beta cells.15 When these cells 
are destroyed by the body’s immune system, their ability to secrete insulin is 
compromised.15 As a result, the ability of glucose to enter cells is diminished and, 
consequently, blood glucose levels remain elevated.15 
  
Risk Factors and Potential Causes of T1D 
 
 Both genetic susceptibility and environmental factors are believed to be involved 
in triggering T1D.16 The prevailing hypothesis on the cause of T1D is that exposure to 
one or more environmental agents in a person with genetic susceptibility triggers and/or 
potentiates an autoimmune attack on pancreatic beta cells, the underlying 
pathophysiology of T1D.16  
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There are several genes that have been found to be associated with an increased 
risk of developing T1D. These genes can be divided into two groups: MHC genes and 
non-MHC genes. MHC, or major histocompatibility complex, genes encode a set of 
proteins that are located on cell surfaces.17 Due to the role these proteins play in immune 
system activation and regulation, MHC gene/protein variants have been found to be 
associated with autoimmune disease, although the specific mechanisms behind this 
association are not well-understood.17 More than 40 non-MHC gene variants have been 
identified that increase susceptibility to T1D.18 
 Although susceptibility to T1D appears to be inherited, the specific transmission 
pattern in unknown.18 The general population has an estimated 0.55% chance of 
developing T1D.18 Offspring of fathers with T1D have an approximately 12% chance of 
developing the disease, while offspring of mothers with T1D have an approximately 6% 
chance.18 Siblings of individuals with the disease have a 5-10% chance of developing the 
disease by age 20, a 15-fold greater risk than the general population.18 Studies among 
twin siblings found that if one has the disease, a monozygotic twin has a 13-33% chance 
of having it as well, whereas a dizygotic twin has 6-10% chance.18 
 It is believed that environmental factors trigger and/or potentiate an autoimmune 
reaction against pancreatic beta cells in genetically susceptible patients.16 While much 
uncertainty remains regarding the specific environmental agents that are responsible, 
there is evidence that environmental factors are indeed involved in the pathogenesis of 
T1D. Firstly, a very small portion of genetically susceptible people develop T1D, 
suggesting that some factor beyond genetics is required to develop the disease.16 This is 
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further supported by the aforementioned data from studies on genetically identical 
twins.18 Furthermore, there are drastically different incidence rates among people of the 
same genetic background living in different geographic regions. For example, among 
Caucasian children under 15 years old, the incidence rate is 3.2/100,000 in Macedonia, 
while in Finland it is 63/100,000.16 Moreover, studies of migrants have shown that the 
incidence of the disease increases when they move from a region of lower incidence to a 
region of higher incidence, further implicating environmental conditions as triggers of the 
disease.16 
 While no specific environmental agents have been proven to trigger T1D, there 
has been research on the association of different agents, in particular viruses, dietary 
factors, and the gut microbiome, with the disease. Viruses may trigger an autoimmune 
response against pancreatic beta cells via molecular mimicry.16 The enterovirus genus has 
been particularly implicated in the development of the disease.19 Several dietary factors, 
including exposure to cow’s milk, breastfeeding, Vitamin D levels, and Omega-3 fatty 
acid levels, have been studied in the setting of T1D.16,20 Data from multiple studies 
suggest that Omega-3 fatty acids protect against the development of pancreatic beta cell 
autoimmunity and T1D,16,20 but the effect of other dietary factors on the pathogenesis of 
T1D remains controversial and unclear. Studies suggest that imbalances in gut 
microbiome composition may play a role in the development of T1D,16,20 but causative 
associations between specific intestinal microbes and/or specific microflora compositions 
and T1D have not been established. 
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Epidemiology of T1D 
 
 T1D accounts for 5-10% of cases of diabetes mellitus worldwide with type 2 
diabetes (T2D), a form of diabetes that involves insulin resistance due to obesity and 
insufficient exercise, accounting for the other cases.21 Although T2D is becoming more 
prevalent in children and adolescents, T1D remains the most common type in these age 
groups, accounting for more than 85% of diabetes mellitus cases in people younger than 
20 years of age worldwide.22 Two large studies have investigated the epidemiology of 
T1D in children and adolescents: the World Health Organization’s DIAMOND Project 
looked at trends worldwide, while the SEARCH Study, an ongoing multicenter study, has 
looked at trends in the United States.  
 Published in 2000, the DIAMOND Project23 investigated the incidence of T1D 
worldwide in children less than or equal to 14 years of age between the years 1990-1994. 
Among the populations that were studied, they found an approximately 350-fold 
difference in incidence rates. For example, in China and Venezuela, incidence rates were 
0.1/100,000 per year, while in Sardinia, Italy the incidence rate was 36.8/100,000 per 
year. Countries with the lowest incidence rates (<1/100,000 per year) included China and 
South American countries and countries with the highest incidence rates (>20/100,000 
per year) included the Scandinavian countries, Italy, Canada, and New Zealand. The 
incidence rates in different US populations ranged from 10-20/100,000 per year.  The 
study also found that, in most populations, incidence rates increased with age with the 
highest incidence rates in those 10 to 14 years old. Finally, the study also found that 
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between 1990 and 1994, there was an average annual increase in incidence rates 
worldwide of 2.8%.23 
 The SEARCH for Diabetes in Youth Study is an ongoing, multicenter study 
investigating the epidemiology of T1D in the United States. One sub-study from 
SEARCH found that the overall prevalence of T1D in people less than 20 years old in 
2001 was 1.82/1,000 people.24 Another sub-study investigated T1D incidence in people 
younger than 20 years old and found that the incidence rates were highest in non-
Hispanic white youth, slightly higher in females compared to males, and highest in the 5-
9 and 10-14 age ranges.25 Another study that used data from the SEARCH Study found 
that the incidence of T1D increased from 14.8/100,000 people per year in 1988 to 
23.9/100,000 people per year in 2004.26 Lastly, a sub-study estimated that from 1978-
2004, the overall incidence of T1D increased by approximately 2.3% per year.22 Together 
these studies suggest that the incidence of T1D among children and adolescents is 
increasing both in the US and worldwide.  
 
Clinical Presentation of T1D 
 
T1D is a disease of youth: approximately ¾ of people with the disease are 
diagnosed prior to their 18th birthday.3 Patients can present with signs and symptoms of 
T1D or diabetic ketoacidosis (DKA), a serious complication of the disease, or the disease 
can be discovered incidentally in an asymptomatic patient.3 A prospective study by 
Roche et al3 investigated the presenting features in patients under 15 years old with 
incident cases of T1D in Ireland in 1997 and 1998. The study found that across all age 
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categories, the combination of polyuria and polydipsia was the most common 
presentation scenario with 66-75% of patients, depending on age ranges, presenting this 
way. The study found that weight loss was the next most common presenting sign with 
22-45% of patients, depending on age, presenting with this. The study also found that 
25% of patients presented in moderate to severe diabetic ketoacidosis.3  
 A retrospective study by Al Rashed et al27 investigated clinical presentation 
patterns in children and adolescents with T1D in Saudi Arabia. Similar to Roche et al, the 
study found that the most common presenting signs and symptoms were polyuria, 
polydipsia, and weight loss. Al Rashed found that 92% of patients presented with 
polyuria and 88.8% presented with polydipsia. Of note, these percentages are slightly 
higher compared to Roche et al’s results. Al Rashed found that 32.9% of patients 
presented with weight loss, which is similar to what Roche et al found. Additionally, Al 
Rashed found that 47.2% of patients presented with moderate to severe DKA, which is 
higher than what Roche et al found, which may reflect a relative lack of healthcare 
knowledge in the study region.27  
 These two studies highlight that the most common presenting signs/symptoms in 
a child or adolescent with new onset T1D include polyuria, polydipsia, and weight loss 
and that a quarter to half of patients with new onset T1D will present in some form of 
diabetic ketoacidosis.  
 
Diagnosis of T1D 
 
Any of the following criteria can constitute a diagnosis of diabetes of any type, 
including T1D and T2D: 1) classic symptoms of diabetes, such as polyuria, polydipsia, 
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and unexplained weight loss, and a random plasma glucose level of greater than or equal 
to 200 mg/dl; 2) a fasting (no food intake for at least 8 hours) plasma glucose level of 
greater than or equal to 126 mg/dl on two consecutive days; or 3) a plasma glucose level 
of 200 mg/dl or greater 2 hours after an oral glucose tolerance test.28  
 Once a diagnosis of diabetes has been confirmed, the provider must determine 
whether the patient has T1D or T2D because the treatment of these two types could be 
different. In the past, children and adolescents who were diagnosed with diabetes nearly 
always had T1D.28 However, the incidence of T2D is rapidly increasing in children and 
adolescents, which complicates the diagnosis of diabetes in this age group.28 The 
presence of autoantibodies to pancreatic autoantigens points toward T1D, but cannot be 
used to definitively diagnose T1D because these autoantibodies can also be present in 
patients with T2D.29 Therefore, providers have to consider a variety of other factors, 
including the patient’s age, body habitus, and family history, to help distinguish T1D and 
T2D.28 The vast majority of youth with T1D present before the age of 14, while the vast 
majority of youth with T2D present at the onset of puberty or later.25 Non-obese youth 
with diabetes typically have T1D, while obese patients with diabetes typically have 
T2D.30  Up to 10% of patients with T1D will have a first-degree family member who also 
has the disease, while up to 90% of patients with T2D will have a first-degree family 
member with the disease.31  
 
Management of T1D: Blood Glucose Monitoring 
 
 Given that T1D is characterized by the insufficient production of insulin and, 
consequently, the potential for elevated blood glucose levels, management of T1D 
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involves frequent monitoring of blood glucose levels and the administration of exogenous 
insulin to maintain appropriate glucose homeostasis. Both hyperglycemia and 
hypoglycemia are associated with multiple complications28,39 so the goal for patients with 
T1D is to maintain blood glucose levels within a particular range that minimizes the risk 
of these complications.  
 The most recent recommendations from both the American Diabetes Association 
(ADA) and the International Society for Pediatric and Adolescent Diabetes (ISPAD) 
suggest that adolescents ages 13-18 should have a target Hemoglobin A1C (HgA1C; a 
marker of average blood glucose levels over the prior 2-3 months) goal of <7.5%.28,32 The 
ADA notes that this number is higher than the target for adults (<7%) because of the 
physiological and behavioral challenges that adolescents face, which makes glycemic 
control more difficult to achieve. The ADA also notes that blood glucose and HgA1C 
targets should ultimately be individualized with the goal of maximizing glycemic control 
while minimizing the risk of severe hypoglycemia.32  
 People with T1D need to monitor their blood glucose levels frequently each day 
so that they can appropriately adjust their dietary intake of glucose and can administer the 
correct amount of insulin to maintain their blood glucose level within a healthy range. 
There are two main strategies for blood glucose monitoring: self-monitoring of blood 
glucose (SMBG), which typically involves multiple daily fingersticks, and continuous 
glucose monitoring (CGM), which involves continuous measurement of blood glucose 
levels via a minimally invasive subcutaneous device.4 Per ISPAD recommendations, 
SMBG should be performed prior to meals, two hours after food intake, at bedtime, 
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during the night, and after the overnight fast to detect and prevent hypoglycemia and 
hyperglycemia and to optimize insulin dosing.4 Increased frequency of SMBG correlates 
with better glycemic control.4  
In addition to eliminating the need for multiple daily fingersticks, which can be 
time-intensive and uncomfortable, a notable benefit of CGM is that these devices can be 
programmed to alarm when glucose levels trend towards dangerously low levels or when 
there are rapid fluctuations in glucose levels.33 Hence, CGM is especially helpful for 
people who have hypoglycemia unawareness.33 A study comparing SMBG and CGM 
with respect to changes in HgA1C found that adults (age 25 and older) who used CGM 
achieved a significantly greater reduction in HgA1C compared to those who used SMBG 
but found no significant differences in HgA1C among subjects between eight and 24 
years old.33 However, the study also found that frequency of CGM use was the best 
predictor of HgA1C lowering for all age-groups and, specifically, found that subjects age 
25 and older wore the CGM devices significantly more than those younger than 25, 
which likely largely explains the differences in outcomes.33 Therefore, insufficient use 
of/poor adherence to CGM devices is an important limitation to CGM in adolescents. 
Other barriers to CGM include cost, lack of insurance coverage, and lack of availability 
in some countries.34   
 
Management of T1D: Insulin  
 
 In addition to blood glucose monitoring, insulin therapy is the other cornerstone 
of T1D management. There are several different types of insulin based on their duration 
   
 13 
of action in the body: short-, intermediate-, and long-acting.5 To achieve and maintain 
optimal glycemic control, the ideal strategy for insulin administration is “basal-bolus” 
therapy, which involves administering a long-acting insulin to maintain a basal level in 
the body and supplementing this with boluses of short-acting insulin to account for 
mealtime increases in blood glucose levels.5  
There are several different methods for insulin administration. Multiple daily 
injections  (MDI) is one method. This involves using either syringes and needles or 
insulin “pens,” which are prefilled with a certain amount of insulin, to administer basal 
and bolus doses of insulin at appropriate times during the day.5  
Another method involves the use of an insulin pump, or continuous subcutaneous 
insulin infusion (CSII). These devices are programmed to continuously administer insulin 
at a set basal rate.5 However, users must check their blood glucose levels frequently 
throughout the day and manually adjust the insulin dose/infusion rate accordingly.5 Users 
must also manually increase the insulin dose/infusion rate to deliver mealtime boluses.5 
Newer technology has integrated insulin pumps with CGM. With this “sensor-augmented 
pump therapy,” users monitor their blood glucose with the CGM device, then manually 
adjust their insulin dose/infusion rate via the insulin pump.35 A newer variation of this 
technology, “sensor-augmented pump therapy with threshold suspension,” directly links 
the CGM with the CSII device and programs the insulin pump to terminate insulin 
delivery when the CGM device senses a preset low threshold blood glucose level.36  
The newest technology in insulin administration involves “closed-loop” insulin 
pumps, or the “artificial pancreas,” of which there are two types. The hybrid closed-loop 
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system is comprised of CGM technology and an insulin pump that uses an algorithm to 
automatically adjust basal insulin delivery based on CGM readings.37 With this 
technology, users are still required to manually increase the insulin dose/infusion rate to 
deliver mealtime boluses.37 Another type of closed-loop pump is the automated closed-
loop system, which is similar to the hybrid closed-loop system, but which is fully 
automatic- users do not have to manually adjust the insulin dose/infusion rate at all.38 
 
Complications of T1D 
 
 There are multiple potential acute and chronic complications in patients with 
T1D. The most common acute complication is hypoglycemia, which is loosely defined as 
a blood glucose level less than 65 mg/dl.39 In children, severe hypoglycemia can result in 
seizures and/or loss of consciousness.39 Another acute complication is diabetic 
ketoacidosis (DKA), a life-threatening condition that results when, due to a shortage of 
insulin, the body is no longer able to use glucose as fuel and, therefore, starts 
metabolizing fatty acids.28 This results in the production of ketone bodies, which increase 
the acidity in the blood.28 Many patients with undiagnosed T1D often present with DKA 
and many T1D patients who fail to adhere to their insulin regimens rapidly develop 
DKA.28 
 Vascular sequelae represent some of the most significant and burdensome long-
term complications of T1D. Vascular complications include microvascular (nephropathy, 
retinopathy, and neuropathy) and macrovascular (coronary artery disease, 
cerebrovascular disease, and peripheral vascular disease) complications.40 The 
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pathophysiology of how chronic/uncontrolled diabetes leads to these complications is not 
completely understood.40 These complications typically take many years to manifest 
clinically and are rarely seen overtly in children and adolescents.40 However, there is 
evidence that the pathophysiological processes underlying these complications begin 
around the time of disease onset and that these complications can be detected clinically 
and with laboratory data as early as 2-5 years after a patient is diagnosed.40 Therefore, it 
is important that children and adolescents with T1D are regularly screened for these 
complications as part of disease management.   
 T1D in children and adolescents has also been shown to be a risk factor for a 
variety of psychiatric disorders. A prospective cohort study by Butwicka et al7 found that 
children and adolescents with T1D were 2.1 times more likely to be diagnosed with a 
psychiatric disorder compared to peers without T1D (HR = 2.1, 95% CI: 2.0, 2.2). 
Specifically, the study found that youth with T1D were at a significantly increased risk 
for mood disorders, anxiety disorders, eating disorders, substance misuse, ADHD, 
behavioral disorders, and intellectual disability compared to youth without T1D.7 
Additionally, a retrospective cohort study by Cooper et al41 that looked at the incidence 
of psychiatric disorders in subjects who were diagnosed with T1D before age 18 found 
that subjects with T1D were 2.3 times more likely to be diagnosed with a psychiatric 
disorder compared to peers without T1D (HR= 2.3, 95% CI: 1.9, 2.7). Furthermore, a 
prospective cohort study by Dybdal et al42 found that youth with T1D were 1.55 times 
more likely to be diagnosed with a psychiatric disorder compared to peers without T1D 
(HR= 1.55, 95% CI: 1.38, 1.74). Like Butwicka et al, both Cooper et al and Dybdal et al 
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specifically found that youth with T1D were at a significantly increased risk for mood 
disorders, anxiety disorders, eating disorders, and behavior disorders.41,42 Ultimately, 
these studies all suggest that youth with T1D are at a significantly increased risk of 
developing a psychiatric disorder compared to youth without T1D.  
 
Depression and T1D 
 
As mentioned above, psychiatric disorders, and in particular anxiety, depression, 
and eating disorders, are common in children and adolescents with T1D.7,41,42 Multiple 
studies suggest that children and adolescents with T1D have increased rates of psychiatric 
disorders compared to peers without T1D.7,41,42 Additionally, there is evidence that 
suggests that the presence and severity of psychiatric disorders affect T1D monitoring, 
management, and clinical outcomes.10,45,46,47 Ultimately, the evidence suggests that 
psychiatric disorders are commonly present in children and adolescents with T1D and can 
significantly impact the clinical course of the disease. Depression, in particular, is a 
common psychiatric comorbidity in children and adolescents with T1D and can have a 
devastating impact on the management and clinical outcomes of T1D.  
 
Epidemiology of Depression in Children and Adolescents with T1D 
Multiple studies have found that depression is a common comorbidity in children 
and adolescents with T1D.7,8,41,42 For example, a study by Kovacs et al8 followed 92 
youths who were diagnosed with T1D between the ages of 8 and 13. The study followed 
this cohort for 10 years and found that by the 10th year, 47.6% of the patients had 
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developed a psychiatric disorder. In particular, the study found that 27.5% of the group 
had developed major depression, the most prevalent psychiatric disorder among the 
cohort.8 
 The vast majority of the evidence also suggests that children and adolescents with 
T1D are at higher risk of depression than the general population of children and 
adolescents. A prospective cohort study by Butwicka et al7 used data from the Swedish 
Childhood Diabetes Register to identify patients younger than 18 with T1D. For each of 
these individuals, the study identified 100 controls matched for age, sex, and county of 
birth. The study then followed all subjects until their eighteenth birthday to investigate 
whether subjects developed psychiatric disorders. The study found that subjects with T1D 
were 2.1-times more likely to be diagnosed with a psychiatric disorder compared to 
controls and, in particular, found that patients with T1D were at increased risk for mood 
disorders, such as depression (HR= 2.0, 95% CI: 1.8, 2.3). Interestingly, this study 
determined the risk of developing a psychiatric disorder among siblings of both the 
cohort with T1D and the control cohort who did not have a diagnosis of T1D before age 
18 and found no significant difference between these sibling groups,7 suggesting that 
genetics did not play a significant role in the development of mood disorders among the 
patients with T1D. This is a high-quality study: there were over 17,000 patients with T1D 
enrolled and the controls were well-matched. This study provides strong evidence that 
children and adolescents with T1D have a higher risk of depression than the general 
population of children and adolescents. 
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 A prospective cohort study by Dybdal et al42 reached this same conclusion. The 
study identified 5,084 children and adolescents in two Danish national health registries 
who were diagnosed with T1D before their eighteenth birthday, then matched these 
individuals with controls (matched for age and sex). The study followed subjects to 
determine whether they developed psychiatric disorders, including depression. The study 
found that the incidence of mood disorders, including depression, in both boys and girls 
with T1D was higher than in matched controls (for boys: HR= 1.95, 95% CI: 1.52, 2.51, 
and for girls: HR= 1.55, 95% CI: 1.27, 1.89).42 Similar to Butwicka et al, this study was 
of high quality; it enrolled a large number of patients with T1D and had well-matched 
controls. It also reached the same conclusion as the Butwicka study: children and 
adolescents with T1D have a higher risk of depression than the general population of 
children and adolescents.  
Another study from Australia supports the conclusions of Butwicka et al and 
Dybdal et al. A prospective cohort study by Cooper et al41 used the Western Australia 
Childhood Diabetes Database and identified 1,302 subjects who were diagnosed with 
T1D before their eighteenth birthday. The study then prospectively followed this cohort 
and 6,422 age- and sex-matched controls into early adulthood (average age at the end of 
follow up for both cohorts was 26.4 years). The study found that the incidence of 
depression in subjects with T1D was significantly higher than in controls (HR = 2.95, 
95% CI: 2.3, 3.8).41 This study differs from the Butwicka et al and Dybdal et al in that it 
followed subjects past their eighteenth birthdays and into early adulthood, but it 
ultimately parallels the findings of these other two studies in demonstrating that children 
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and adolescents who are diagnosed with T1D are at increased risk of developing 
depression relative to the general population of children and adolescents.  
Butwicka et al, Dybdal et al, and Cooper et al are all high-quality studies: they are 
population-based, prospective cohort studies that include thousands of youth with T1D 
and have well-matched controls. However, a notable weakness of these studies relates to 
their use of national registers to gather data on psychiatric diagnoses. It is likely that 
youth with T1D in these studies had more exposure to healthcare providers and, for this 
reason, it is possible that they were more likely to be diagnosed with a psychiatric 
disorder or be referred to a mental health clinician compared to non-diabetic peers. 
Individual assessment of all subjects for psychiatric disorders would have eliminated this 
referral and diagnostic bias. However, use of national registers precludes individual 
assessment of all subjects for psychiatric disorders and, therefore, each of these studies is 
limited by referral and diagnostic biases. Furthermore, although these three studies took 
place in three different countries and the results are similar across all three countries, the 
populations of Sweden, Denmark, and Australia are less diverse compared to other 
countries, which suggests that these results may not be generalizable across multiple 
countries or ethnicities.  
 A meta-analysis by Reynolds and Helgeson43 in 2011 evaluated studies since 
1990 that compared children and adolescents with and without T1D with regards to 
psychological well-being, including depressive symptoms and clinical depression. The 
study calculated aggregate effect sizes (Cohen’s d values) for different variables (i.e. 
clinical depression), which reflected the magnitude of the difference between groups. The 
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study found that children with T1D had more depressive symptoms and clinical 
depression versus children without T1D and, based on the Cohen’s d value, found the 
effect size to be “medium.” Interestingly, the study found that the effect size decreased 
with more recent studies, perhaps suggesting that the prevalence and severity of 
depression in children and adolescents with T1D has been decreasing in severity in recent 
years. Nonetheless, the authors concluded that youth with T1D are at a slightly increased 
risk for psychological disorders, including depression, compared to peers without T1D.43  
 However, not all studies have concluded that youth with T1D are at increased risk 
of developing depression compared to youth without the disease. Sivertsen et al12 
conducted a cross-sectional study of adolescents in a single county in Norway to compare 
the prevalence of psychiatric comorbidities, including depression, in youth with and 
without T1D. The study found that 6.5% of youth with T1D had depression, while 5.8% 
of youth without T1D had depression (p = 0.28). The authors concluded that there was no 
significant difference in the prevalence of depression among these two groups. They did 
note that their conclusion contrasted with the vast majority of prior studies, which had 
found an increased risk of depression among youth with T1D. They stated that this lack 
of difference might be due to the fact that the study was conducted relatively recently 
(2012) in Norway and that, at that time, a significant number of youths had started using 
CSII instead of MDI. They hypothesized that this might explain the lack of a significant 
difference in depression prevalence.12 It is also possible that the lack of statistical 
significance is due to a beta error. Also, because only 40 patients with T1D were 
ultimately enrolled, the study may have been underpowered to detect a significant 
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difference in depression prevalence between those with and without T1D. Furthermore, 
this study has several significant limitations: it only enrolled patients living in a single 
county in Norway born between 1993 and 1995, which suggests that results are not 
generalizable; it allowed patients to self-report a diagnosis of diabetes without 
differentiating between T1D and T2D, then relied on reviews of medication lists to 
determine whether patients had T1D or T2D; and finally, no diagnoses were verified by 
clinicians and lab data were not available. 
 Ultimately, research findings suggest that youth with T1D are at increased risk of 
depression compared youth without T1D; Butwicka et al, Dybdal et al, and Cooper et al 
report significant hazard ratios between 1.55 and 2.95. The findings of Reynolds and 
Helgeson and Silvertsen et al do suggest that the incidence and prevalence of depression 
in youth with T1D may have started decreasing in recent years but, overall, the data 
suggest that there is a significant difference in the incidence and prevalence of depression 
in youth with and without T1D.   
 
Explanations for the Increased Risk of Depression in Youth with T1D 
 
 Youth with T1D are at greater risk than their peers without the disease for 
developing depression and several studies have investigated reasons for this association. 
A diagnosis of T1D yields psychological stressors that can lead to depressive symptoms. 
For example, the knowledge that the disease is chronic/lifelong and the constant, looming 
threat of future complications can make youth more prone to depression.43,44 A diagnosis 
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can also result in decreased self-esteem, which can make an adolescent more prone to 
depression.44  
The nature of T1D management can also be a factor in the development of 
depression. Disease management is demanding and stressful.8 Youth with T1D have to 
check their blood glucose level multiple times throughout the day, keep track of their 
physical activity and carbohydrate intake, properly administer insulin, and quickly correct 
any abnormalities in their blood glucose levels.43 This constant burden and stress, as well 
as the persistent fear of hypoglycemia, can lead to depression.43 Additionally, the burden 
of diabetes management and poor control of diabetes can lead to family tension, as well 
as feelings of guilt and hopelessness in the adolescent, all of which can contribute to 
depression.9 The disease also has the capacity to disrupt normal childhood activities, such 
as school, sports, and peer group social interactions, which can make youth with T1D 
more prone to psychological disorders, including depression.43  
Grey et al44 also note a new, hypothetical, physiological explanation for the 
development of depression in adolescents with T1D. Imbalances in GABA, a major 
neurotransmitter in the brain, are hypothesized to play a role in the pathophysiology of 
depression. Autoantibodies to glutamic acid decarboxylase, present in approximately 
70% of adolescents with T1D, have been found to alter the synthesis of GABA. This 
suggests that autoantibodies involved in the pathogenesis of T1D may also play a role in 
the pathophysiology of depression.44  
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The burden of living with and managing a chronic, complex disease and a 
potential biochemical association between diabetes and depression may explain why 
adolescents with T1D are at increased risk for depression compared to their healthy peers. 
 
Association between Depression, Adherence, and Glycemic Control 
 
 Given that depression is more prevalent in youth with T1D, it is important to 
consider the effect that depression has on adherence to monitoring and treatment 
regimens, as well as on clinical outcomes, in youth with T1D. A study by McGrady et 
al10 investigated the associations between depression and both blood glucose monitoring 
frequency (a marker of adherence to disease management) and HgA1C (a marker of 
glycemic control). This prospective observational study involved 144 adolescents (ages 
13-18) with T1D. The study gathered baseline data on depression symptoms (via the 
Children’s Depression Inventory, or CDI), blood glucose monitoring frequency, and 
HgA1C, and then gathered this same data six months later. The authors found that 
increased total CDI scores (indicating increased depression symptoms) correlated with 
decreased blood glucose monitoring frequency both initially (r = -0.29, p < 0.001) and at 
follow-up (r = -0.16, p < 0.05) and that increases in the specific depression symptoms of 
negative mood, ineffectiveness, and negative self-esteem correlated with decreased blood 
glucose monitoring frequency both initially and at follow-up (p < 0.05). Increased total 
CDI scores also correlated with increased HgA1C initially (r = 0.26, p < 0.01) and at 
follow-up (r = 0.12, p > 0.05), although the correlation at follow-up did not reach 
statistical significance. The authors concluded that increased depression symptoms, 
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particularly negative mood, ineffectiveness, and negative self-esteem, correlated with 
decreased frequency of blood glucose monitoring and worsened glycemic control.10 
A study by Hood et al45 reached similar conclusions but also identified an 
interesting three-way interaction between depression, blood glucose monitoring, and 
glycemic control. This was a prospective observational study that sought to determine the 
effect of depression on glycemic control in adolescents. The study enrolled 145 
adolescents (age 13-18) with T1D. The study gathered data on depression symptoms, the 
frequency of blood glucose monitoring, and HgA1C at the initial study visit and again six 
months later. The results showed that increases in depression symptoms were associated 
with increases in HgA1C values. Specifically, every increase of 5 points on the CDI was 
associated with a 0.5% increase in HgA1C. Interestingly, in patients who experienced 
increased depression symptomatology, an increase in the frequency of blood glucose 
monitoring was associated with smaller increases in HgA1C. However, a decrease in the 
frequency of blood glucose monitoring acted synergistically with increased depression 
symptoms and resulted in notable increases in HgA1C.45 The authors concluded that 
depression symptoms can predict HgA1C and that this relationship may be mediated by 
changes in the frequency of blood glucose monitoring.  
McGrady and Laffel et al46 also performed a study that found that depression 
worsens glycemic control and that the effect of depression on glycemic control can be 
mediated by blood glucose monitoring. They performed a cross-sectional study that 
involved 276 adolescents with T1D. They gathered data on depression symptoms using 
the CDI, blood glucose monitoring frequency, and HgA1C. They found that increases in 
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depression symptoms were associated with a lower frequency of blood glucose 
monitoring (p = 0.02) and higher HgA1C/poorer glycemic control (p = 0.05). However, 
when they looked at the effect of both depression symptoms and blood glucose 
monitoring frequency on glycemic control at the same time, the effect of blood glucose 
monitoring frequency was significant (p < 0.001), but the effect of depression symptoms 
was no longer significant (p = 0.19). This result led them to conclude that blood glucose 
monitoring can mediate the relationship between depression symptoms and glycemic 
control. They used the Sobel test to determine the magnitude of the mediation effect and 
concluded that blood glucose monitoring frequency can account for 37.5% of the link 
between depression and glycemic control (p <0.05).46 This means, for example, that the 
worse a patient’s depression is, the poorer their glycemic control will likely be but if they 
monitor their blood glucose quite frequently, their glycemic control will be better than 
expected based on the severity of their depression.  
A study by Hilliard et al47 also found that depression severity correlates with 
poorer disease management and outcomes. This prospective observational study sought 
to determine which factors predict deteriorations in adherence to T1D management and 
glycemic control in adolescents. The study identified 150 adolescents (ages 13-18) with 
T1D, followed these subjects for 18-24 months, and separated them into three groups 
based on adherence to disease management (blood glucose monitoring frequency) and 
glycemic control (HgA1C). The three groups were “meeting treatment targets,” “not 
meeting treatment targets,” and “high risk.” The study then sought to determine which 
variables predicted membership in each of these subgroups. A key finding was that, when 
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comparing subjects in the “meeting treatment targets” and “not meeting treatment 
targets” group, increased depression symptoms (based on CDI scores) predicted 
membership in the “not meeting treatment targets” group (OR = 1.07, p < 0.05). The 
study noted that an increase in a subject’s CDI score by one standard deviation made 
them 1.61 times more likely to be in the “not meeting treatment targets” group compared 
to the “meeting treatment targets” group.47  
The findings from these four studies suggest that in adolescents with T1D, 
increased severity of depression is associated with poorer adherence to disease 
management and poorer glycemic control. The data also suggest that the association 
between depression and glycemic control can be mediated by blood glucose monitoring 
frequency. Although these four studies reach the same conclusions and the majority of 
their findings on the association between depression, adherence, and glycemic control 
reach statistical significance, there are several limitations that the studies share. Firstly, 
the three prospective cohort studies had relatively short follow-up periods (6-24 months). 
They were able to show that worsening depression is associated with poorer adherence 
and glycemic control over 6-24 months but, given adolescence is a five-year period, it 
would have been interesting to see whether those associations and/or the magnitude of 
those associations held over a longer period of time. Additionally, each of the four studies 
employed the CDI score, which is based on self-reporting, to characterize the subjects’ 
depression. It would have been optimal to have a licensed clinician evaluate and score the 
subjects’ depression. Furthermore, the only variable used to assess adherence to the 
diabetes management regimen in each of the studies was blood glucose monitoring 
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frequency. There are several other important components to disease management, 
including appropriate dosing and timing of insulin administration and dietary factors, that 
were not considered. These could have had an effect on glycemic control independent of 
blood glucose monitoring. Finally, there was very little heterogeneity in the study 
populations - each of the studies noted that the vast majority of their subjects were 
Caucasian with intact families. This limits the generalizability of these studies’ findings. 
Despite these flaws, the findings suggest that depression is associated with poorer 
adherence and poorer glycemic control in adolescents with T1D.  
 
Explanations for Why Depression is Associated with Poorer Adherence and  
 
Glycemic Control  
 
 Several studies have put forth explanations for the association between depression 
symptoms and glycemic control in youth with T1D. Depression symptoms can include 
negative mood, loss of energy, hopelessness, indecisiveness, anhedonia, and pessimism.10 
These symptoms may impede adolescents from finding the motivation to initiate and 
complete diabetes management tasks and can also make them believe their efforts will be 
unsuccessful.10 Depression can also lead to memory impairment, diminished 
concentration, and low energy, all of which can limit an adolescent’s capacity to perform 
the complicated cognitive tasks required to manage their disease.44 Decreased motivation 
and diminished cognitive capacity can result in poor disease management, and 
consequently, poor glycemic control.45  
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Association Between Depression and Hospitalizations for T1D 
 
 T1D has acute complications, notably hypoglycemia and DKA, that can lead to 
hospitalization. Hypoglycemia and DKA can both result from failure to properly manage 
the disease (for example, inadequate carbohydrate intake or administration of too much 
insulin in the case of hypoglycemia, or failure to administer an adequate amount of 
insulin in the case of DKA). A couple of studies have investigated the effect of 
depression on hospitalizations for complications of T1D. Stewart et al11 performed a 
prospective observational study that sought to determine whether depressive symptoms 
predict hospitalization in youth with T1D. The study enrolled 231 children and 
adolescents (ages 11-18) with T1D. The subjects self-rated their depression symptoms 
using the Center for Epidemiological Studies Depression Scale (CES-D). The CES-D 
score ranges from 0-60. The cutoff scores for detecting depression were 12 for boys and 
22 for girls.  The subjects were then followed for two years and their hospitalizations for 
complications from T1D were tracked. After controlling for gender, age, socioeconomic 
status, and HgA1C, each of which has been found to independently predict 
hospitalization in youth with T1D, subjects whose CES-D scores fell above the cutoff 
points were more than 2.5-times more likely to be hospitalized for complications from 
T1D compared to subjects whose CES-D scores fell below the cutoff points (HR = 2.58, 
95% CI: 1.12, 5.98).11 These results suggest that increased depression symptoms increase 
the likelihood that youth with T1D will be hospitalized due to complications from their 
disease. This study’s limitations include recruitment from a single medical center, which 
limits the generalizability of the results; self-reporting of depressive symptoms, which 
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limits the validity of the results; and a short follow-up time period. However, the fact that 
a large number of youth (231) were enrolled and that the study controlled for several 
other variables that can predict hospitalizations point to the strength of this study.  
 Furthermore, a prospective cohort study by Garrison et al48 sought to determine 
whether the presence of psychiatric disorders, including depression, has an effect on 
rehospitalization in youth who were hospitalized for complications of T1D. This study 
used the Pediatric Health System Database in the United States to identify 3,094 
adolescents (ages 13-18) who were hospitalized due to diabetes complications. The 
presence or absence of comorbid psychiatric diagnoses at the time of discharge was 
noted, then the subjects were followed from the time of discharge for 24 months to look 
for rehospitalizations. The study found that 16% of the adolescents were rehospitalized at 
least once during the follow-up period and that internalizing disorders, including 
depression and anxiety, were associated with repeat admissions (OR = 1.79, 95% CI: 
1.27, 2.52, p < 0.01). There was no significant association between externalizing 
disorders (i.e. impulsivity, aggression) and repeat hospitalizations.48 The results 
ultimately suggest that comorbid internalizing disorders, including depression, are 
associated with a significantly increased risk of re-hospitalizations in adolescents with 
diabetes. Of note, the study included adolescents with both T1D and T2D, however, the 
study controlled for this potential confounder during analysis.48 The studies by Stewart et 
al and Garrison et al suggest that depression significantly increases the risk of both 
hospitalizations and rehospitalizations due to complications of T1D.  
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T1D, Depression, and Suicide 
 
 Suicide is an important consideration in youth with T1D given that youth with the 
disease have access to insulin and administration of too much insulin can be lethal. There 
is evidence that T1D is a risk factor for suicide. A prospective cohort study by Goldston 
et al49 found adolescents with T1D were more likely to experience suicidal ideation than 
the general population. The lifetime prevalence of suicidal ideation among the 91 
adolescents with T1D in their study was 26.4%, more than double the prevalence found 
by two other studies on the general population of adolescents. However, the study did not 
find that adolescents with T1D were more likely to attempt suicide compared to the 
general population. This study also found that adolescents with T1D who had a history of 
suicidal ideation were three times more likely to be noncompliant with their medical 
regimen compared to adolescents with T1D who had never had suicidal ideation (p < 
0.001).49 Interestingly, a more recent prospective cohort study by Butwicka et al7 found 
that youth with T1D were 1.7 times more likely to attempt suicide compared to youth 
without T1D (HR = 1.7, 95% CI: 1.4, 2.0). The findings of these two studies suggest that 
adolescents with T1D are at higher risk for suicidal ideation and suicidal attempts 
compared to adolescents without T1D and that suicidal ideation can negatively impact 
adherence to treatment regimens.  
 
Effect of Insulin Pumps on Quality of Life 
 
 To date, there have been no studies that have specifically investigated whether 
depression symptomatology is different between youth using MDI and CSII. However, 
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several studies have compared quality of life in children and adolescents using MDI and 
CSII. Hirose et al50 noted that measures of quality of life in youth with T1D include 
lifestyle flexibility, feeling safe, perceiving positive and supportive relationships with 
family and friends, self-efficacy, anxiety, and fear of hypoglycemia and other 
complications. Many of these quality of life measures are associated with the 
development of depression. For example, fear of hypoglycemia has been identified as a 
cause of depression in youth with T1D.50  
Mednick et al51 (2004) performed a cross-sectional study to investigate quality of 
life in youth with T1D following transition from MDI to CSII. The study enrolled 22 
youth ages 10-18 who had all been using MDI prior to transitioning to CSII. The study 
used surveys to gather data on satisfaction with CSII and quality of life; surveys were 
completed after the transition to CSII. The results of the CSII satisfaction surveys showed 
that subjects reported greatest satisfaction with the flexibility related to eating and 
sleeping that CSII provided relative to MDI. Quality of life survey results showed 
improvements in perceived quality of life after transitioning to CSII, mostly due to 
increased flexibility with diet and leisure activities. The results also showed that 
satisfaction with CSII was significantly positively correlated with quality of life (r = 0.51, 
p < 0.05).51 The cross-sectional design of this study is a limitation- subjects did not 
complete surveys while using MDI, which did not allow for comparison of quality of life 
data while using MDI versus CSII. Nevertheless, the authors did note that this pilot study 
identified specific areas of satisfaction associated with CSII use relative to MDI use and 
showed an association between CSII use and quality of life.  
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A prospective cohort study by McMahon et al13 (2004) found that children and 
adolescents with T1D who commenced CSII experienced statistically significant 
improvements in the quality of life measures “impact of diabetes on the patient” and 
“self-efficacy with diabetes” (p < 0.05) after six months of using CSII, which the authors 
attributed to the increased lifestyle flexibility and increased independence that pump 
therapy allows for relative to MDI. The results did not show statistically significant 
improvements in the quality of life measures “worries about diabetes” and “satisfaction 
with life.” A notable limitation of this study is that only approximately half of the 
subjects were using MDI prior to starting CSII, while the other half initiated therapy with 
CSII shortly after diagnosis. This calls into question the extent to which the 
improvements in quality of life measures were due to inherent benefits of CSII compared 
to MDI versus a novelty effect of starting a new treatment. Additionally, quality of life 
data was gathered via self-report questionnaires, which could limit the validity of the 
results. The authors noted that therapies that improve quality of life may have long-term 
benefits, including decreasing the risk of depression, and they noted that it would be 
important to determine the specific effect of CSII compared to MDI on depression over 
long periods of time.13  
Nuboer et al14 (2008) performed a randomized controlled trial investigating the 
effects of CSII use compared to MDI use on quality of life. All subjects used MDI during 
a 3.5-month run-in phase, then subjects were randomized to MDI or CSII for 3.5 months, 
and then all subjects continued with CSII for another seven months. There was not a 
statistically significant difference in quality of life, measured by PedsQL (Pediatric 
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Quality of Life Inventory), when comparing the MDI group and the CSII group at the end 
of the 3.5 month randomization phase. However, those randomized to MDI experienced a 
statistically significant (p < 0.05) increase in quality of life from the end of the 
randomization period to the end of a subsequent 3.5 month period of using CSII. 
Additionally, an analysis of all children in the study showed a statistically significant 
increase in quality of life from the end of the randomization period to the end of the study 
(p = 0.023). This result suggests that quality of life improves after switching from MDI to 
CSII. Additionally, the study also used the Diabetes Quality of Life Questionnaire to 
measure the “impact of disease” on the subjects. A within-patient analysis of  “impact of 
disease” scores showed that the “impact of the disease” decreased significantly from the 
end of the randomization period to the end of the study (p = 0.0063),14 which suggest that 
the “impact of disease” lessens after switching from MDI to CSII. Unlike in McMahon et 
al, all subjects in this study used both MDI and CSII at some point, which allowed for a 
much more accurate comparison of the relative quality of life impact of the two methods. 
Additionally, most subjects in the McMahon et al study were started on CSII by request, 
which represents a significant selection bias. In contrast, subjects in Nuboer et al were 
randomized into either the MDI or CSII group. Two weaknesses of this study are its 
limited power, given that there were only 19 subjects in each study arm, and its reliance 
on self-report questionnaires, which could limit the validity of the results. As discussed 
above, although the study does not specifically address depression, the PedsQL and 
Diabetes Quality of Life Questionnaire include measures of quality of life, which are 
associated with the risk of developing depression.  
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Alsaleh et al52 (2014) performed a study to investigate the impact of switching 
from MDI to CSII on quality of life in children and adolescents. The authors used face-
to-face, semi-structured interviews to gather qualitative data from 34 youth ages 5-17. 
The authors found that 18 of the 34 youth reported increased comfort and autonomy with 
management of their disease with CSII compared to MDI; 25 of the 34 youth reported 
that CSII made it easier for them to take part in activities such as going to restaurants, 
parties, travelling, camping, and playing; 24 of the 34 youth reported CSII did not have a 
negative impact on education in school compared to MDI; 31 of the 34 youth reported 
using CSII at school did not negatively impact social interaction with peers compared to 
MDI; and 30 of the 34 youth reported CSII did not negatively affect participation in 
sports/extracurriculars. The authors concluded that use of CSII did not negatively impact 
quality of life compared to use of MDI and, in many ways, use of CSII improved quality 
of life compared to use of MDI. A notable limitation of this study is the use of semi-
structured interview to collect data- questions may not have been asked in a uniform 
manner to all subjects, which could have skewed the data. However, the study is unique 
compared to other studies that have addressed this topic in that it gathered qualitative, not 
quantitative data. It also reached the same conclusion as Mednick et al, McMahon et al, 
and Nuboer et al: use of CSII can improve quality of life compared to use of MDI.  
Weintrob et al53 (2003) performed a randomized cross-over study to investigate 
treatment satisfaction and quality of life differences with use of MDI compared to CSII. 
The study enrolled 23 youth aged 8-14 with T1D who had been treated with MDI for at 
least two years. The 23 subjects were randomly assigned to use either MDI or CSII for 
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3.5 months, then subjects used the other mode of therapy for another 3.5 months. 
Subjects completed the Diabetes Treatment Satisfaction Questionnaire (DTSQ) and the 
Diabetes Quality of Life Questionnaire (DQOL) at the beginning of the study and at the 
end of each of the two treatment periods. The results showed a significant increase in 
treatment satisfaction at the end of the CSII treatment period compared to at the 
beginning of the study and at the end of the MDI period (p < 0.001). The results did not 
show statistically significant improvement in any of three quality of life measures at the 
end of the CSII period compared to at the beginning of the study and at the end of the 
MDI period. The authors noted that at the end of the study, 16 of the 23 youth said they 
would prefer to continue with CSII, due to the increased flexibility with mealtimes it 
allowed for compared to MDI and elimination of painful injections. The randomization of 
subjects into treatment groups and the use of both MDI and CSII by all subjects are 
strengths of this study. Nevertheless, the results of this study contrast with the four 
aforementioned studies in that they do not suggest that use of CSII results in improved 
quality of life compared to use of MDI. However, given that only 23 subjects were 
enrolled in the study, the study may not have been powered to detect a significant 
difference in quality of life.  
Although the aforementioned studies that investigated quality of life in youth 
using MDI and CSII are limited by small sample sizes and reliance on self-report 
questionnaires, the majority of the studies suggest that youth using CSII may have a 
better quality of life compared to those using MDI.  
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A review by Hirose et al50 provides several reasons for why CSII may improve 
quality of life. The authors note that T1D places significant demands on youth. These 
include: frequently monitoring blood glucose levels; frequently administering insulin via 
syringes, pens, or pumps; timing blood glucose monitoring and insulin administration 
with respect to meals, exercise, and bedtime; monitoring dietary intake; and avoiding 
acute fluctuations in blood glucose levels. They note that these demands can undoubtedly 
have an adverse effect on quality of life. However, they note that CSII gives patients the 
ability to make more precise adjustments to basal and bolus insulin doses compared to 
MDI, allows for more flexibility in timing of meals, and gives adolescents increased 
independence and responsibility for their management/treatment regimens, and that these 
factors may explain why CSII is associated with improved quality of life relative to 
MDI.50  
The findings discussed above suggest that CSII can improve quality of life 
relative to MDI. Although measures of quality of life are associated with the risk of 
developing depression, there do not appear to be any studies that specifically address 
differences in the effect of CSII versus MDI on depression symptomatology in youth 
with T1D. While the vast majority of studies suggest youth with T1D are at higher risk 
for depression compared to peers without the disease, the study by Sivertsen et al12 in 
2014 found no significant difference in prevalence of depression between adolescents 
with and without T1D. Although the study did not track how many adolescents used CSII 
or MDI, they did note that CSII had become very popular in the country the study took 
place in and hypothesized that this increased usage of CSII may explain the lack of a 
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significant difference in depression between the two cohorts. However, they did note that 
there are other plausible explanations for this lack of significant difference and they noted 
several significant limitations to their study.12  
The majority of the data suggests that CSII improves quality of life compared to 
MDI: it decreases the burden of disease management, lessens the fear of acute and 
chronic complications, and leads to less disruption in normal childhood activities 
compared to MDI.  Since there is an association between quality of life and the risk of 
developing depression, it follows that CSII may decrease depression symptomatology 
relative to MDI. However, there do not appear to be any studies that specifically address 
whether this is the case.    
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METHODS 
Study Design 
 
A multiple-center, prospective cohort study will be conducted to compare 
depression symptoms in youth ages 10-17 who have recently been diagnosed with T1D 
who are initiating therapy with either 1) multiple daily injections of insulin (MDI) or 2) 
continuous subcutaneous insulin infusion via an insulin pump (CSII). The Children’s 
Depression Inventory (CDI-2) will be used to obtain data about subjects’ depression 
symptoms at diagnosis, at six months, and at 12 months. 
 
Study Population and Sampling 
 
The source population from which the study sample will be drawn is youth 10 
years old and 17 years old who have recently been diagnosed with T1D and who will be 
initiating therapy with one of two treatment regimens (see Exposure Groups). Inclusion 
criteria include a diagnosis of T1D according to the American Diabetes Association; age 
10 and 17 years old; and initiating therapy with either MDI or CSII.  Exclusion criteria 
include prior or current use of MDI, CSII, or closed-loop devices; initiating therapy with 
a closed-loop device; prior or current use of blood glucose monitoring devices; prior 
diagnosis of a psychiatric disorder (mood disorder including depression and bipolar 
disorder, anxiety, eating disorder, schizophrenia, ADD/ADHD); inability of the youth to 
read English at a second grade level; inability of at least one parent/guardian to 
demonstrate competence with management of their child’s treatment regimen; and 
presence of another chronic disease (e.g. inflammatory bowel disease, cancer).  
   
 39 
Subjects will be recruited from the SEARCH for Diabetes in Youth (SEARCH) 
study database. The SEARCH study is an ongoing, multicenter, observational study that 
began in 2000 with the goal of understanding more about diabetes in youth in the United 
States.54  The study uses active surveillance to maintain a registry of youth under age 20 
who have been diagnosed with diabetes (both T1D and T2D). This registry allows for the 
assessment of prevalence, annual incidence, and trends by diabetes type, age, race, and 
sex. The SEARCH study centers and registry have been used extensively for ancillary 
studies.55 There are SEARCH study centers in five different states and some centers have 
multiple locations. These centers actively surveil certain geographically defined 
populations in each state: seven counties in (Southern) California, the entire state of 
Colorado, eight counties in Ohio, the entire state of South Carolina, and five counties in 
Washington. Overall, the study surveils 6.2% of the US population younger than 20 years 
old.25  
 A study by Mayer-Davis et al that analyzed data from the SEARCH study found 
that the yearly incidence of T1D in people 0-19 years old in the geographical regions 
covered by the SEARCH study ranged from 916 to 1101 (with an average of 1022) 
between 2003 and 2012.54 It has been found that approximately half of youth age 0-19 
with type 1 diabetes will be diagnosed when 9 years old and approximately half will be 
diagnosed when 10 years old.25 Thus, the SEARCH study identifies and enrolls 
approximately 500 incident cases of T1D in youth ages 10-17 per year.  
 A study by Miller et al in 2015 found that 65% of 6-12 year-olds and 58% of 13-
17 year-olds with T1D in the United States were using CSII, while the rest were using 
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MDI.56 A review by Prahalad et al in 2018 found that 47% of 9½-15 year olds with T1D 
in the United States were using CSII.57 Given this, we estimate that approximately 50% 
of 10-17 year-olds with newly diagnosed T1D will initiate therapy with MDI and 50% 
will initiate therapy with CSII.   
 Given that the SEARCH study identifies and enrolls approximately 500 incident 
cases of T1D in youth ages 10-17 per year, we estimate that of these 500 cases, 
approximately 250 youth will initiate therapy with MDI and approximately 250 will 
initiate therapy with CSII. Extrapolating these data over three years, we expect there to be 
approximately 750 youth in the SEARCH study initiating therapy with MDI and 750 
youth initiating therapy with CSII. Given the limited time requirements of this study and 
the ease of participation, we expect at least 80% of potential subjects to consent, so we 
expect to enroll approximately 600 youth initiating therapy with MDI and 600 youth 
initiating therapy with CSII.  
 Using these estimates, as well as an alpha of 0.05 and a beta of 0.2, this study will 
have 80% power to detect an effect size of 0.162 standard deviations in CDI-2 score, 
which is considered a “small” effect size based on Cohen’s d calculations.58 
 
Exposure Groups 
 
There will be two exposure groups, or cohorts, in this study. Both cohorts will 
include youth 10 and 17 years old who were recently diagnosed with T1D. One cohort 
will include youth who are initiating therapy with MDI. The other cohort will include 
youth who are initiating therapy with CSII. 
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Study Variables and Measures 
The primary outcome is severity of depression symptoms. Depression symptoms 
will be measured by the Children’s Depression Inventory 2 (CDI-2), a self-report 
questionnaire that is widely used to evaluate depression symptoms in youth ages 7-17.10 
Youth rate 27 items on a scale from 0 to 2. The total score can range from 0-54. Higher 
scores indicate more depression symptomatology.46 While different cutoff scores for 
clinically significant depression have been proposed, a cutoff score of  13 is considered 
to be sensitive for detecting clinically significant depression.45  
 
Recruitment 
 
The SEARCH registry will be reviewed daily by research assistants to identify 
youth with a new diagnosis of T1D. These youth and their families will then be contacted 
by telephone to introduce and describe the study and to gauge interest. If there is interest 
in enrolling in the study, a research assistant will meet with the youth and their family at 
the youth’s next scheduled follow-up appointment, which will likely involve meetings 
with a multidisciplinary team and the initiation of a treatment regimen for T1D. The 
research assistant will further describe the study and assess the youth for 
inclusion/exclusion criteria. If the youth meets inclusion/exclusion criteria and they and 
their family wish to proceed with the study, informed consent will be obtained from a 
parent and assent will be obtained from the youth.  
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Data Collection 
 
 Demographic data including age, gender, race/ethnicity, state and county of 
residence, and center the patient was recruited from will be obtained from the SEARCH 
database and will be entered into an Excel spreadsheet on an encrypted computer by a 
research assistant. Additionally, the exposure group that the patient is in will be entered 
into the spreadsheet by a research assistant. 
 Subjects will fill out a paper-based version of the CDI-2 around the time of their 
diagnosis and again at follow-up visits six and 12 months later.  A research assistant will 
be present to provide the subjects with the survey and will be present while the subject is 
filling out the survey. The research assistant will then collect and score the survey and 
enter the score into the Excel spreadsheet using an encrypted computer. The paper-based 
CDI-2 will then be stored in a locked cabinet in the research assistant’s office space.  
 
Data Analysis 
 
For each of the two cohorts, a mean (with standard deviation) CDI score will be 
calculated at diagnosis, six months, and 12 months. At each of the three time intervals, a 
Student’s t-test will be performed to compare CDI scores between the two cohorts.  
 Of note, we will review each subject’s medical chart prior to them completing 
CDI-2 surveys at six and 12 months. If they have switched to a new method of insulin 
administration since they completed the last survey, they will be excluded from analysis.  
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Timeline and Resources 
 
 We expect IRB approval will take approximately 1 month. Recruitment of 
subjects will take place over a three year period (which will allow for a total sample size 
of approximately 1,500 subjects) and since subjects will be followed for one year, the 
total length of time that the study will be following subjects will be approximately four 
years. We expect data analysis will take approximately 1 month. Study personnel will 
include the primary investigator, a statistician, and five research assistants (one for each 
of the SEARCH study centers). The study will also require three paper-based CDI 
surveys for each of the subjects, as well as statistical software. 
 
Institutional Review Board 
 
We will submit this study proposal for review by the IRB at each of the SEARCH 
centers and the Boston University Medical Center IRB. Given that this study involves 
administering surveys to children under the age of 18, we will apply for a full board 
review.  
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CONCLUSION 
Discussion 
 
 The proposed prospective cohort study will compare depression symptoms in 
youth ages 10-17 who have recently been diagnosed with T1D who are initiating therapy 
with either MDI or CSII.  The study will seek to determine whether the use of CSII 
results in decreased depression symptomatology compared to the use of MDI. 
 A key strength of this study is that it will be the first to investigate the association 
between method of insulin administration and depression symptomatology. Another 
strength is that it will employ the SEARCH study sites and surveillance data. The 
SEARCH study surveils an estimated 6.2% of the US population under 20 years old and 
its surveillance range includes five different states across the US. Thus, the results will be 
quite generalizable to the entire US.   
 The study design does have limitations. First, we are measuring depression 
symptomatology over time, not presence or absence of clinically significant depression. 
Although different threshold CDI scores have been proposed to indicate clinically 
significant depression, we are gathering data on depression symptomatology. We are not 
determining whether subjects have clinically significant depression. Therefore, although 
we may observe a statistically significant difference in depression scores between groups 
by the end of the study, the results may not actually be clinically significant.  
 We must also consider the hypothetical physiological explanation that has been 
proposed to explain why individuals with T1D are at higher risk for depression- 
autoantibodies to GAD, which are involved in the pathogenesis of T1D, may cause an 
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imbalance in GABA, which could then result in depression.44 Further research is needed 
to determine the role of this hypothetical phenomenon, but we must note that if this 
phenomenon plays a role in the pathogenesis of depression in youth with T1D, we may 
not see as large a difference in depression symptomatology in our two cohorts are we 
expect to.  
 Closed-loop insulin pumps are the newest insulin administration technology for 
patients with T1D. Given the limited use of this technology compared to MDI and CSII at 
this time, this study will not investigate the effect of closed-loop pumps on depression 
symptomatology. However, given that closed-loop pumps theoretically decrease the 
burden of disease management compared to MDI and CSII, an important follow-up study 
will be to investigate the effect of closed-loop pumps of depression symptomatology 
compared to MDI and CSII.   
  
Summary 
 
 T1D is an autoimmune disease that involves destruction of pancreatic beta cells 
and, consequently, hyperglycemia. The disease typically presents in children and 
adolescents. Management of the disease involves frequent monitoring of blood glucose 
levels and administration of exogenous insulin. Youth with T1D have been found to be at 
increased risk of depression compared to peers without T1D, which is thought to be due 
to the burden of disease management, disruption of normal childhood activities, fear of 
complications, and decreased self-esteem that the disease brings. The presence and 
severity of depression symptoms in youth with T1D have been shown to correlate with 
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clinical outcomes, hospitalizations and rehospitalizations for disease complications, and 
suicidal ideation. In recent years, CSII has emerged as an option for management of T1D, 
in addition to MDI. Results from a limited number of studies suggest that use of CSII 
improves youths’ quality of life compared to use of MDI. Although these quality of life 
factors are associated with the development of depression, there are no studies that 
specifically address the effect of use of MDI compared to CSII on depression symptoms 
in youth with T1D. This proposed project will seek to compare depression 
symptomatology in youth using MDI and CSII over the course of a year.  
 
Clinical Significance 
 
 There are several factors that inform a clinician’s decision about whether to use 
MDI or CSII. If the results of this study show that depression symptomatology is 
significantly lower in those using CSII compared to MDI, clinicians could use this to 
inform their decision about whether to start youth on MDI or CSII.  
 Additionally, not all insurance companies currently cover insulin pumps. 
However, if the results of this study show that depression symptomatology is 
significantly lower in those using CSII compared to MDI, insurance companies may be 
more inclined to pay for pumps, as the extra cost of the pump may be offset by a decrease 
in mental health clinic visits and a decrease in prescriptions for anti-depressive 
medications. However, this would require further analysis of the data to determine if 
there was a clinically significant difference in depression symptomatology.  
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